Building Portfolios That Hold: From Clinical Trial to Courtroom

21st and 22nd April, 2027 | Hyatt Regency, Boston

Two days of practical patent strategy for life sciences IP teams.

300+

ATTENDEES

60+

EXPERT SPEAKERS

20+

SESSIONS

Life sciences patent strategy is being pulled in every direction at once: a more discretionary PTAB, shifting §101 and §112 rules, drug pricing pressure, and AI compressing the time between discovery and disclosure. LSPN brings together the in-house counsel, private practice attorneys and service providers who deal with it every day, for candid conversation you can act on the following Monday.

Across two days you’ll hear regional overviews covering the US, UPC, Brazil, Europe and China. You’ll also get panels running from clinical-stage filing strategy to Hatch-Waxman, biosimilar thickets and mRNA platform disputes, plus 24 roundtable topics, in-house only sessions and hands-on tool test drives.

WHAT’S NEW IN 2027

We’ve reworked the format from the ground up.

Arrive Already Among Friends

Networking drinks and twilight registration the evening before.

Speak Candidly

In-house only sessions for small groups of 20 to 30, away from the main stage.

Build Your Own Experience

Panels, roundtables and tool test drives run in different rooms, so you can shape the two days around your priorities.

Choose More Roundtables

They now run concurrently, so you can join more of the conversations that matter to you.

Take It All Home

Every attendee gets the post-event report, slides and session recordings.

KEY THEMES

Navigate the Regulatory & Patent Landscape

From USPTO eligibility guidance and a more discretionary PTAB to the UPC and EPO, build exclusivity strategies that hold across jurisdictions.

Master IP Deal-Making

Valuation, due diligence and collaboration agreements, so in-licensed IP and shared improvements keep their value after signing.

Defend Market Exclusivity

Hatch-Waxman litigation, Orange Book scrutiny, biosimilar thickets and mRNA disputes—how to build portfolios that are enforceable from drafting to courtroom.

Optimise Your Portfolio Under Budget Pressure

Decide where to file, what to maintain and what to prune, while keeping outside counsel costs in check.

Keep Pace with the Science

AI in prosecution and drug discovery, trade secrets versus patents, and emerging modalities including gene therapy and antibodies.

WHO YOU’LL MEET

Network with senior leaders from across the life sciences IP ecosystem.

49%

In-House Counsel

42%

Private Practice

Service Providers

Companies in the room included

Novartis Takeda Sanofi Regeneron Gilead Bristol Myers Squibb Alnylam BioNTech Beam Therapeutics

DON'T JUST TAKE OUR WORD FOR IT

SWIPE OR SCROLL RIGHT TO VIEW MORE →

“LSPN is my favorite patent conference - hands down! The content is timely and insightful. The audience is energetic and the conversations are helpful. Highly recommend this conference for all life science practitioners.”

Stephanie Schonewald

Choate Hall & Stewart

“LSPN is becoming the best IP conference in the US, bringing together active professionals worldwide who work at firms as well as in-house. The conference is a great way of staying up-to-date on the latest in patent law, topics that are becoming important, as well as reuniting with colleagues in the industry.”

Dominic Yee

Kymera Therapeutics

“The event is now the premier LS IP event. Its continued growth and the enthusiasm and participation of the attendees evidence its recognition within the LS community.”

James Haley Jr

Leason Ellis

“Informative, educational, and a great opportunity to reconnect with colleagues and meet new ones.”

Mark Nickas

Alnylam Pharmaceuticals

“Just a really wonderful conference focusing on important topics in our field. The diversity of attendees, from law firms, international, and in-house folks as well as the overall high level of expertise made it a particularly rewarding experience.”

MJ Edwards

Gilead Sciences

“This conference brings together many of the key thought leaders and in-house decision-makers on the front lines of life sciences intellectual property law to share insights and learn from each other. It should not be missed.”

Barbara Fiacco

Foley Hoag

“Important topics discussed to provide insightful observations and strategies! I always leave with many implementable takeaways.”

Dhara Patel

Director IP & Contracts Counsel, Souffle Therapeutics

“LSPN is a great conference to attend for the life sciences IP practitioner. It always has relevant topics and thoughtful insights from participants, all in an efficient format that allows ample time to network and connect with colleagues.”

Michael Penn

Vice President, Intellectual Property, BlueRock Therapeutics

“Excellent agenda with highly relevant topics, supported by strong presentations and insightful panel discussions. It was a pleasure to be part of this event, which is definitely a key forum for staying connected with the pharma community.”

Eva Ehlich

Maiwald

“LSPN was wonderful. I learned so much and had the opportunity to meet new people in the IP community. Will be back next year!”

Judith Kuntz

Ipsen

“From the quality of the speakers to the highly relevant content and exceptional networking opportunities, it was truly one of the best conferences we've attended.”